ALY is a common coactivator of RUNX1 and c-Myb on the type B leukemogenic virus enhancer

Journal of Virology

Volumn 81, Issue 7, 2007, Pages 3503-3513

  Mertz, Jennifer A ^a   Kobayashi, Ryuji ^b   Dudley, Jaquelin P ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NUCLEAR FACTOR; PROTEIN C MYB; RUNX1B PROTEIN; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG; VIRUS DNA;

ALY GENE; ANIMAL CELL; ARTICLE; BINDING AFFINITY; BINDING SITE; CELL SPECIFICITY; DNA BINDING; DNA INTEGRATION; ENHANCER REGION; GENE ACTIVATION; GENE DELETION; GENE IDENTIFICATION; GENE OVEREXPRESSION; GENE VECTOR; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; LEUKEMIA CELL LINE; LEUKEMIA VIRUS; LONG TERMINAL REPEAT; LYMPHOMA; MASS SPECTROMETRY; MOLECULAR INTERACTION; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN PURIFICATION; REPORTER GENE; SEQUENCE ANALYSIS; T CELL LEUKEMIA; T LYMPHOCYTE; TYPE B LEUKEMOGENIC VIRUS;

ANIMALS; BINDING SITES; CELL LINE; CORE BINDING FACTOR ALPHA 2 SUBUNIT; ENHANCER ELEMENTS (GENETICS); HUMANS; MICE; MOLECULAR SEQUENCE DATA; MUTATION; NUCLEAR PROTEINS; PROMOTER REGIONS (GENETICS); PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-MYB; RETROVIRIDAE; RNA-BINDING PROTEINS; TRANSCRIPTION FACTORS; UP-REGULATION;

MOUSE MAMMARY TUMOR VIRUS;

EID: 33947380548     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.02253-06     Document Type: Article

References (55)

1. Allen, R. D., III, H. K. Kim, S. D. Sarafova, and G. Siu. 2001. Negative regulation of CD4 gene expression by a HES-1-c-Myb complex. Mol. Cell. Biol. 21:3071-3082.
2. Aratoft, H. W., A. B. Sørensen, C. Bareil, J. Schmidt, A. Luz, and F. S. Pedersen. 1997. Stability of AML1 (core) site enhancer mutations in T lymphomas induced by attenuated SL3-3 murine leukemia virus mutants. J. Virol. 71:5080-5087.
3. Ball, J. K., L. O. Arthur, and G. A. Dekaban. 1985. The involvement of a type-B retrovirus in the induction of thymic lymphomas. Virology 140:159-172.
4. Ball, J. K., G. A. Dekaban, J. A. McCarter, and S. M. Loosmore. 1983. Molecular biological characterization of a highly leukaemogenic virus isolated from the mouse. III. Identity with mouse mammary tumour virus. J. Gen. Virol. 64:2177-2190.
5. Ball, J. K., H. Diggelmann, G. A. Dekaban, G. F. Grossi, R. Semmler, P. A. Waight, and R. F. Fletcher. 1988. Alterations in the U3 region of the long terminal repeat of an infectious thymotropic type B retrovirus. J. Virol. 62:2985-2993.
6. Ball, R. K., R. R. Friis, C. A. Schoenenberger, W. Doppler, and B. Groner. 1988. Prolactin regulation of beta-casein gene expression and of a cytosolic 120-kd protein in a cloned mouse mammary epithelial cell line. EMBO J. 7:2089-2095.
7. Berge, T., S. L. Bergholtz, K. B. Andersson, and O. S. Gabrielsen. 2001. A novel yeast system for in vivo selection of recognition sequences: defining an optimal c-Myb-responsive element. Nucleic Acids Res. 29:E99.
8. Bies, J., S. Feikova, D. P. Bottaro, and L. Wolff. 2000. Hyperphosphorylation and increased proteolytic breakdown of c-Myb induced by the inhibition of Ser/Thr protein phosphatases. Oncogene 19:2846-2854.
9. Blum, K. A., G. Lozanski, and J. C. Byrd. 2004. Adult Burkitt leukemia and lymphoma. Blood 104:3009-3020.
10. Bosselut, R., F. Lim, P. C. Romond, J. Frampton, J. Brady, and J. Ghysdael. 1992. Myb protein binds to multiple sites in the human T cell lymphotropic virus type 1 long terminal repeat and transactivates LTR-mediated expression. Virology 186:764-769.
11. Bramblett, D., C. L. Hsu, M. Lozano, K. Earnest, C. Fabritius, and J. Dudley. 1995. A redundant nuclear protein binding site contributes to negative regulation of the mouse mammary tumor virus long terminal repeat. J. Virol. 69:7868-7876.
12. Britos-Bray, M., and A. D. Friedman. 1997. Core binding factor cannot synergistically activate the myeloperoxidase proximal enhancer in immature myeloid cells without c-Myb. Mol. Cell. Biol. 17:5127-5135.
13. Broussard, D. R., M. M. Lozano, and J. P. Dudley. 2004. Rory (Rorc) is a common integration site in type B leukemogenic virus-induced T-cell lymphomas. J. Virol. 78:4943-4946.
14. Broussard, D. R., J. A. Mertz, M. Lozano, and J. P. Dudley. 2002. Selection for c-myc integration sites in polyclonal T-cell lymphomas. J. Virol. 76:2087-2099.
15. Bruhn, L., A. Munnerlyn, and R. Grosschedl. 1997. ALY, a context-dependent coactivator of LEF-1 and AML-1, is required for TCRα enhancer function. Genes Dev. 11:640-653.
16. Carabana, J., E. Ortigoza, and M. S. Krangel. 2005. Regulation of the murine D82 promoter by upstream stimulatory factor 1, Runx1, and c-Myb. J. Immunol. 174:4144-4152.
17. Chattopadhyay, C., D. Hawke, R. Kobayashi, and S. N. Maity. 2004. Human p32, interacts with B subunit of the CCAAT-binding factor, CBF/NF-Y, and inhibits CBF-mediated transcription activation in vitro. Nucleic Acids Res. 32:3632-3641.
18. Chen, C., and H. Okayama. 1987. High-efficiency transformation of mammalian cells by plasmid DNA. Mol. Cell. Biol. 7:2745-2752.
19. Del Monaco, M., S. P. Covello, S. H. Kennedy, G. Gilinger, G. Litwack, and J. Uitto. 1997. Identification of novel glucocorticoid-response elements in human elastin promoter and demonstration of nucleotide sequence specificity of the receptor binding. J. Investig. Dermatol. 108:938-942.
20. Djokic, M., M. M. Le Beau, L. J. Swinnen, S. M. Smith, C. M. Rubin, J. Anastasi, and K. M. Carlson. 2006. Post-transplant lymphoproliferative disorder subtypes correlate with different recurring chromosomal abnormalities. Genes Chromosomes Cancer 45:313-318.
21. DuBridge, R. B., P. Tang, H. C. Hsia, P. M. Leong, J. H. Miller, and M. P. Calos. 1987. Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system. Mol. Cell. Biol. 7:379-387.
22. Finstad, S. L., S. Prabhu, K. R. Rulli, and L. S. Levy. 2004. Regulation of FeLV-945 by c-Myb binding and CBP recruitment to the LTR. Virol. J. 1:3.
23. Ganter, B., S. T. Chao, and J. S. Lipsick. 1999. Transcriptional activation by the Myb proteins requires a specific local promoter structure. FEBS Lett. 460:401-410.
24. Golemis, E., Y. Li, T. N. Fredrickson, J. W. Hartley, and N. Hopkins. 1989. Distinct segments within the enhancer region collaborate to specify the type of leukemia induced by nondefective Friend and Moloney viruses. J. Virol. 63:328-337.
25. Hernandez-Munain, C., and M. S. Krangel. 1994. Regulation of the T-cell receptor 8 enhancer by functional cooperation between c-Myb and core-binding factors. Mol. Cell. Biol. 14:473-483.
26. Howcroft, T. K., J. D. Weissman, A. Gegonne, and D. S. Singer. 2005. A T lymphocyte-specific transcription complex containing RUNX1 activates MHC class I expression. J. Immunol. 174:2106-2115.
27. Hsiang, Y. H., J. P. Goldman, and D. H. Raulet. 1995. The role of c-Myb or a related factor in regulating the T cell receptor γ gene enhancer. J. Immunol. 154:5195-5204.
28. Hsu, S. C., J. Galceran, and R. Grosschedl. 1998. Modulation of transcriptional regulation by LEF-1 in response to Wnt-1 signaling and association with p-catenin. Mol. Cell. Biol. 18:4807-4818.
29. Kim, K. J., C. Kaneilopoulos-Langevin, R. M. Merwin, D. H. Sachs, and R. Asofsky. 1979. Establishment and characterization of BALB/c lymphoma lines with B cell properties. J. Immunol. 122:549-554.
30. Landsberg, M. J., K. Moran-Jones, and R. Smith. 2006. Molecular recognition of an RNA trafficking element by heterogeneous nuclear ribonucleoprotein A2. Biochemistry 45:3943-3951.
31. Lenz, J., D. Celander, R. L. Crowther, R. Patarca, D. W. Perkins, and W. A. Haseitine. 1984. Determination of the leukaemogenicity of a murine retrovirus by sequences within the long terminal repeat. Nature 308:467-470.
32. Li, Y., E. Golemis, J. W. Hartley, and N. Hopkins. 1987. Disease specificity of nondefective Friend and Moloney murine leukemia viruses is controlled by a small number of nucleotides. J. Virol. 61:693-700.
33. Martiney, M. J., K. Rulli, R. Beaty, L. S. Levy, and J. Lenz. 1999. Selection of reversions and suppressors of a mutation in the CBF binding site of a lymphomagenic retrovirus. J. Virol. 73:7599-7606.
34. Melnikova, I. N., B. E. Crute, S. Wang, and N. A. Speck. 1993. Sequence specificity of the core-binding factor. J. Virol. 67:2408-2411.
35. Mertz, J. A., F. Mustafa, S. Meyers, and J. P. Dudley. 2001. Type B leukemogenic virus has a T-cell-specific enhancer that binds AML-1. J. Virol. 75:2174-2184.
36. Mertz, J. A., M. S. Simper, M. M. Lozano, S. M. Payne, and J. P. Dudley. 2005. Mouse mammary tumor virus encodes a self-regulatory RNA export protein and is a complex retrovirus. J. Virol. 79:14737-14747.
37. Meyers, S., P. D. Gottlieb, and J. P. Dudley. 1989. Lymphomas with acquired mouse mammary tumor virus proviruses resemble distinct prethymic and intrathymic phenotypes defined in vivo. J. Immunol. 142:3342-3350.
38. Meyers, S., N. Lenny, and S. W. Hiebert. 1995. The t(8;21) fusion protein interferes with AML-1B-dependent transcriptional activation. Mol. Cell. Biol. 15:1974-1982.
39. Mueller, R. E., L. Baggio, C. A. Kozak, and J. K. Ball. 1992. A common integration locus in type B retrovirus-induced thymic lymphomas. Virology 191:628-637.
40. Mustafa, F., S. Bhadra, D. Johnston, M. Lozano, and J. P. Dudley. 2003. The type B leukemogenic virus truncated superantigen is dispensable for T-cell lymphomagenesis. J. Virol. 77:3866-3870.
41. Nieves, A., L. S. Levy, and J. Lenz. 1997. Importance of a c-Myb binding site for lymphomagenesis by the retrovirus SL3-3. J. Virol. 71:1213-1219.
42. Olnes, M. I., and R. N. Kurl. 1994. Isolation of nuclear extracts from fragile cells: a simplified procedure applied to thymocytes. BioTechniques 17:828-829.
43. Otto, F., M. Lubbert, and M. Stock. 2003. Upstream and downstream targets of RUNX proteins. J. Cell. Biochem. 89:9-18.
44. Rajan, L., D. Broussard, M. Lozano, C. G. Lee, C. A. Kozak, and J. P. Dudley. 2000. The c-myc locus is a common integration site in type B retrovirus-induced T-cell lymphomas. J. Virol. 74:2466-2471.
45. Reed, R., and H. Cheng. 2005. TREX, SR proteins and export of mRNA. Curr. Opin. Cell Biol. 17:269-273.
46. Schneider, U., H. U. Schwenk, and G. Bornkamm. 1977. Characterization of EBV-genome negative "null" and "T" cell lines derived from children with acute lymphoblastic leukemia and leukemic transformed non-Hodgkin lymphoma. Int. J. Cancer 19:621-626.
47. Seo, J., M. M. Lozano, and J. P. Dudley. 2005. Nuclear matrix binding regulates SATB1-mediated transcriptional repression. J. Biol. Chem. 280: 24600-24609.
48. Speck, N. A., B. Renjifo, E. Golemis, T. N. Fredrickson, J. W. Hartley, and N. Hopkins. 1990. Mutation of the core or adjacent LVb elements of the Moloney murine leukemia virus enhancer alters disease specificity. Genes Dev. 4:233-242.
49. Sun, W., B. J. Graves, and N. A. Speck. 1995. Transactivation of the Moloney murine leukemia virus and T-cell receptor 3-chain enhancers by cbf and ets requires intact binding sites for both proteins. J. Virol. 69:4941-4949.
50. Swinburne, I. A., C. A. Meyer, X. S. Liu, P. A. Silver, and A. S. Brodsky. 2006. Genomic localization of RNA binding proteins reveals links between pre-mRNA processing and transcription. Genome Res. 16:912-921.
51. Thomas, J. O., and A. A. Travers. 2001. HMG1 and 2, and related 'architectural' DNA-binding proteins. Trends Biochem. Sci. 26:167-174.
52. Zairean, A. L., A. F. Lewis, B. E. Crute, N. A. Speck, and J. Lenz. 1995. Transcriptional activity of core binding factor a (AML1) and β subunits on murine leukemia virus enhancer cores. J. Virol. 69:2898-2906.
53. Zaiman, A. L., A. Nieves, and J. Lenz. 1998. CBF, Myb, and Ets binding sites are important for activity of the core I element of the murine retrovirus SL3-3 in T lymphocytes. J. Virol. 72:3129-3137.
54. Zhou, Z., M. J. Luo, K. Straesser, J. Katahira, E. Hurt, and R. Reed. 2000. The protein Aly links pre-messenger-RNA splicing to nuclear export in metazoans. Nature 407:401-405.
55. Zhu, Q., K. Gregg, M. Lozano, J. Liu, and J. P. Dudley. 2000. CDP is a repressor of mouse mammary tumor virus expression in the mammary gland. J. Virol. 74:6348-6357.